U.S. FDA Approves TECVAYLI ™( teclistamab- cqyv), the First Bispecific T- cell Engager Antibody for the Treatment of Cases with Regressed or Refractory Multiple Myeloma
U.S. FDA Approves TECVAYLI ™( teclistamab- cqyv), the First Bispecific T- cell Engager Antibody for the Treatment of Cases with Regressed or Refractory Multiple MyelomaTECVAYLI…